Consistent with the findings by Dai et al., who showed that the inhibition of C3 activation reduced serum oxLDL [26], the anti-C5 treatment in the current study lowered circulating oxLDL levels, which may have contributed to the observed reduction in atherosclerosis progression. Here, C5 is linked to atherosclerosis.